JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform. JMP is tracking weekly Factive and Auxilium Pharmaceutical's Testim prescription volumes using NDC Health data. For the week ended Jan. 27, NDC reported that Factive total prescriptions were 6,267, compared with 6,108 total prescriptions in the previous week. Total Testim scripts for the week ended Jan. 27 were 4,977 compared with 4,925 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were up 5 cents, or 2.37%, at $2.16 on volume of 249,311 shares versus the three-month running average of 554,803 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.